- Home
- ETNB vs GSBD Comparison
ETNB vs GSBD Comparison
Compare ETNB & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- GSBD
- Stock Information
- Founded
- ETNB 2018
- GSBD 2012
- Country
- ETNB United States
- GSBD United States
- Employees
- ETNB N/A
- GSBD N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- GSBD Finance: Consumer Services
- Sector
- ETNB Health Care
- GSBD Finance
- Exchange
- ETNB Nasdaq
- GSBD Nasdaq
- Market Cap
- ETNB 1.5B
- GSBD 1.3B
- IPO Year
- ETNB 2019
- GSBD N/A
- Fundamental
- Price
- ETNB $8.87
- GSBD $11.44
- Analyst Decision
- ETNB Strong Buy
- GSBD Sell
- Analyst Count
- ETNB 10
- GSBD 1
- Target Price
- ETNB $27.22
- GSBD $10.00
- AVG Volume (30 Days)
- ETNB 1.5M
- GSBD 602.4K
- Earning Date
- ETNB 11-06-2025
- GSBD 11-06-2025
- Dividend Yield
- ETNB N/A
- GSBD 11.19%
- EPS Growth
- ETNB N/A
- GSBD 52.30
- EPS
- ETNB N/A
- GSBD 1.24
- Revenue
- ETNB N/A
- GSBD $402,124,000.00
- Revenue This Year
- ETNB N/A
- GSBD N/A
- Revenue Next Year
- ETNB N/A
- GSBD N/A
- P/E Ratio
- ETNB N/A
- GSBD $9.22
- Revenue Growth
- ETNB N/A
- GSBD N/A
- 52 Week Low
- ETNB $4.16
- GSBD $9.51
- 52 Week High
- ETNB $11.84
- GSBD $14.54
- Technical
- Relative Strength Index (RSI)
- ETNB 43.45
- GSBD 52.55
- Support Level
- ETNB $8.46
- GSBD $11.31
- Resistance Level
- ETNB $9.47
- GSBD $11.47
- Average True Range (ATR)
- ETNB 0.46
- GSBD 0.13
- MACD
- ETNB -0.02
- GSBD 0.03
- Stochastic Oscillator
- ETNB 33.33
- GSBD 79.14
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About GSBD Goldman Sachs BDC Inc.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.